Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Evaluating New Ophthalmic Digital Devices for Safety and Effectiveness in the Context of Rapid Technological Development.

Bodnar ZM, Schuchard R, Myung D, Tarver ME, Blumenkranz MS, Afshari NA, Humayun MS, Morse C, Nischal K, Repka MX, Sprunger D, Trese M, Eydelman MB.

JAMA Ophthalmol. 2019 Jun 6. doi: 10.1001/jamaophthalmol.2019.1576. [Epub ahead of print]

PMID:
31169870
2.

Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration.

Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, Blumenkranz MS, Constable IJ.

Am J Ophthalmol. 2019 Aug;204:113-123. doi: 10.1016/j.ajo.2019.03.006. Epub 2019 Mar 13.

PMID:
30878487
3.

Validity of the Red Reflex Exam in the Newborn Eye Screening Test Cohort.

Ludwig CA, Callaway NF, Blumenkranz MS, Fredrick DR, Moshfeghi DM.

Ophthalmic Surg Lasers Imaging Retina. 2018 Feb 1;49(2):103-110. doi: 10.3928/23258160-20180129-04.

PMID:
29443359
4.

Comparison of Pneumatic Retinopexy and Scleral Buckle for Primary Rhegmatogenous Retinal Detachment Repair.

Paulus YM, Leung LS, Pilyugina S, Blumenkranz MS.

Ophthalmic Surg Lasers Imaging Retina. 2017 Nov 1;48(11):887-893. doi: 10.3928/23258160-20171030-03.

5.

Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis.

Kapur S, Silverman AP, Ye AZ, Papo N, Jindal D, Blumenkranz MS, Cochran JR.

Bioeng Transl Med. 2017 Mar;2(1):81-91. doi: 10.1002/btm2.10051. Epub 2017 Feb 17.

6.

Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial.

Constable IJ, Lai CM, Magno AL, French MA, Barone SB, Schwartz SD, Blumenkranz MS, Degli-Esposti MA, Rakoczy EP.

Am J Ophthalmol. 2017 May;177:150-158. doi: 10.1016/j.ajo.2017.02.018. Epub 2017 Feb 27.

PMID:
28245970
7.

Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration.

Constable IJ, Pierce CM, Lai CM, Magno AL, Degli-Esposti MA, French MA, McAllister IL, Butler S, Barone SB, Schwartz SD, Blumenkranz MS, Rakoczy EP.

EBioMedicine. 2016 Dec;14:168-175. doi: 10.1016/j.ebiom.2016.11.016. Epub 2016 Nov 10.

8.

Gene Therapy for Age-Related Macular Degeneration.

Constable IJ, Blumenkranz MS, Schwartz SD, Barone S, Lai CM, Rakoczy EP.

Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):300-3. doi: 10.1097/APO.0000000000000222.

PMID:
27488071
9.

What colour are newborns' eyes? Prevalence of iris colour in the Newborn Eye Screening Test (NEST) study.

Ludwig CA, Callaway NF, Fredrick DR, Blumenkranz MS, Moshfeghi DM.

Acta Ophthalmol. 2016 Aug;94(5):485-8. doi: 10.1111/aos.13006. Epub 2016 Apr 7.

10.

Retinal and Optic Nerve Hemorrhages in the Newborn Infant: One-Year Results of the Newborn Eye Screen Test Study.

Callaway NF, Ludwig CA, Blumenkranz MS, Jones JM, Fredrick DR, Moshfeghi DM.

Ophthalmology. 2016 May;123(5):1043-52. doi: 10.1016/j.ophtha.2016.01.004. Epub 2016 Feb 11.

11.

SMARTPHONE-BASED DILATED FUNDUS PHOTOGRAPHY AND NEAR VISUAL ACUITY TESTING AS INEXPENSIVE SCREENING TOOLS TO DETECT REFERRAL WARRANTED DIABETIC EYE DISEASE.

Toy BC, Myung DJ, He L, Pan CK, Chang RT, Polkinhorne A, Merrell D, Foster D, Blumenkranz MS.

Retina. 2016 May;36(5):1000-8. doi: 10.1097/IAE.0000000000000955.

PMID:
26807627
12.

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, Schwartz SD, Blumenkranz MS, Chalberg TW, Degli-Esposti MA, Constable IJ.

Lancet. 2015 Dec 12;386(10011):2395-403. doi: 10.1016/S0140-6736(15)00345-1. Epub 2015 Sep 30.

PMID:
26431823
13.

AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS.

He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T.

Retina. 2016 Mar;36(3):492-8. doi: 10.1097/IAE.0000000000000749.

PMID:
26398694
14.

Serum inflammatory markers after rupture retinal laser injury in mice.

Paulus YM, Kuo CH, Morohoshi K, Nugent A, Zheng LL, Nomoto H, Blumenkranz MS, Palanker D, Ono SJ.

Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):362-8. doi: 10.3928/23258160-20150323-11.

PMID:
25856824
15.

Intravitreal injection technique and monitoring: updated guidelines of an expert panel.

Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, DʼAmico DJ, Dugel PU, Flynn HW Jr, Freund KB, Haller JA, Jumper JM, Liebmann JM, McCannel CA, Mieler WF, Ta CN, Williams GA.

Retina. 2014 Dec;34 Suppl 12:S1-S18. doi: 10.1097/IAE.0000000000000399.

PMID:
25489719
16.

Reply: To PMID 24699157.

Blumenkranz MS.

Am J Ophthalmol. 2015 Jan;159(1):206-7. doi: 10.1016/j.ajo.2014.09.039. No abstract available.

PMID:
25488645
17.
18.

Human histopathology of PASCAL laser burns.

Paulus YM, Kaur K, Egbert PR, Blumenkranz MS, Moshfeghi DM.

Eye (Lond). 2013 Aug;27(8):995-6. doi: 10.1038/eye.2013.100. Epub 2013 May 31. No abstract available.

19.

Herpes simplex virus type 2 mediated acute retinal necrosis in a pediatric population: case series and review.

Silva RA, Berrocal AM, Moshfeghi DM, Blumenkranz MS, Sanislo S, Davis JL.

Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):559-66. doi: 10.1007/s00417-012-2164-8. Epub 2012 Oct 5. Review.

PMID:
23052715
20.

Effect of intravitreal triamcinolone acetonide on healing of retinal photocoagulation lesions.

Nomoto H, Lavinsky D, Paulus YM, Leung LS, Dalal R, Blumenkranz MS, Palanker D.

Retina. 2013 Jan;33(1):63-70. doi: 10.1097/IAE.0b013e318261e34b.

PMID:
23026846
21.

Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.

Leung LS, Silva RA, Blumenkranz MS, Flynn HW Jr, Sanislo SR.

Ophthalmic Surg Lasers Imaging. 2012 Jul 19;43 Online:e73-9. doi: 10.3928/15428877-20120712-05.

PMID:
22823029
22.

Panretinal photocoagulation for proliferative diabetic retinopathy.

Palanker D, Blumenkranz MS.

Am J Ophthalmol. 2012 Apr;153(4):780-1; author reply 781-2. doi: 10.1016/j.ajo.2012.01.001. No abstract available.

PMID:
22445637
23.

Tennis partners.

Flynn HW Jr, Blumenkranz MS.

Retina. 2012 Feb;32 Suppl 1:S12-4. doi: 10.1097/IAE.0b013e31823daa6f. No abstract available.

PMID:
22270764
24.

Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy.

He L, Chan A, Leng T, Blumenkranz MS.

Clin Ophthalmol. 2011;5:1751-8. doi: 10.2147/OPTH.S26631. Epub 2011 Dec 9.

25.

Fifty years of ophthalmic laser therapy.

Palanker DV, Blumenkranz MS, Marmor MF.

Arch Ophthalmol. 2011 Dec;129(12):1613-9. doi: 10.1001/archophthalmol.2011.293. No abstract available.

PMID:
22159684
26.

A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.

Dugel PU, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM, Naor J.

Ophthalmology. 2012 Jan;119(1):124-31. doi: 10.1016/j.ophtha.2011.07.034. Epub 2011 Nov 23.

PMID:
22115710
28.

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J.

Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20.

PMID:
21764136
29.

Femtosecond laser capsulotomy.

Friedman NJ, Palanker DV, Schuele G, Andersen D, Marcellino G, Seibel BS, Batlle J, Feliz R, Talamo JH, Blumenkranz MS, Culbertson WW.

J Cataract Refract Surg. 2011 Jul;37(7):1189-98. doi: 10.1016/j.jcrs.2011.04.022. Erratum in: J Cataract Refract Surg. 2011 Sep;37(9):1742.

PMID:
21700099
30.

The impact of pulse duration and burn grade on size of retinal photocoagulation lesion: implications for pattern density.

Palanker D, Lavinsky D, Blumenkranz MS, Marcellino G.

Retina. 2011 Sep;31(8):1664-9. doi: 10.1097/IAE.0b013e3182115679.

PMID:
21642898
31.

Longterm cultures of the aged human RPE do not maintain epithelial morphology and high transepithelial resistance.

Stanzel BV, Blumenkranz MS, Binder S, Marmor MF.

Graefes Arch Clin Exp Ophthalmol. 2012 Feb;250(2):313-5. doi: 10.1007/s00417-011-1624-x. Epub 2011 Jan 29. No abstract available.

PMID:
21279375
32.

Femtosecond laser-assisted cataract surgery with integrated optical coherence tomography.

Palanker DV, Blumenkranz MS, Andersen D, Wiltberger M, Marcellino G, Gooding P, Angeley D, Schuele G, Woodley B, Simoneau M, Friedman NJ, Seibel B, Batlle J, Feliz R, Talamo J, Culbertson W.

Sci Transl Med. 2010 Nov 17;2(58):58ra85. doi: 10.1126/scitranslmed.3001305.

33.

An extensive case of acute posterior multifocal placoid pigment epitheliopathy.

Chan A, Blumenkranz MS, Sanislo SR.

Retin Cases Brief Rep. 2010 Fall;4(4):336-8. doi: 10.1097/ICB.0b013e3181aff47e.

PMID:
25390912
34.

Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema.

Blumenkranz MS, Haller JA, Kuppermann BD, Williams GA, Ip M, Davis M, Weinberg DV, Chou C, Whitcup SM.

Retina. 2010 Jul-Aug;30(7):1090-4. doi: 10.1097/IAE.0b013e3181dcfaf3.

PMID:
20616686
35.

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group.

Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24.

PMID:
20417567
36.

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group.

Arch Ophthalmol. 2010 Mar;128(3):289-96. doi: 10.1001/archophthalmol.2010.21.

PMID:
20212197
37.

Intravitreous dexamethasone effects on different patterns of diabetic macular edema.

Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS; Dexamethasone DDS Phase II Study Group.

Arch Ophthalmol. 2010 May;128(5):642-3. doi: 10.1001/archophthalmol.2010.44. Epub 2010 Mar 8. No abstract available.

PMID:
20212194
38.

Photoacoustic ocular imaging.

de la Zerda A, Paulus YM, Teed R, Bodapati S, Dollberg Y, Khuri-Yakub BT, Blumenkranz MS, Moshfeghi DM, Gambhir SS.

Opt Lett. 2010 Feb 1;35(3):270-2. doi: 10.1364/OL.35.000270.

39.

Optimal current and future treatments for diabetic macular oedema.

Blumenkranz MS.

Eye (Lond). 2010 Mar;24(3):428-34. doi: 10.1038/eye.2009.335. Epub 2010 Jan 15. Review.

PMID:
20075969
40.

Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: a retrospective comparative study.

Chan A, Blumenkranz MS, Wu KH, Wang G, Berker N, Parast LM, Sanislo SR.

Ophthalmic Surg Lasers Imaging. 2009 Nov-Dec;40(6):561-9. doi: 10.3928/15428877-20091030-05.

PMID:
19928721
41.

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.

Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group.

Am J Ophthalmol. 2009 Jun;147(6):1048-54, 1054.e1-2. doi: 10.1016/j.ajo.2008.12.033. Epub 2009 Mar 9.

PMID:
19268890
42.

Posterior retinal breaks as a cause of vitreous hemorrhage in diabetes.

Hwang TN, Moshfeghi DM, Blumenkranz MS.

Retin Cases Brief Rep. 2008 Fall;2(4):335-7. doi: 10.1097/ICB.0b013e318150697d.

PMID:
25390607
43.

Healing of retinal photocoagulation lesions.

Paulus YM, Jain A, Gariano RF, Stanzel BV, Marmor M, Blumenkranz MS, Palanker D.

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5540-5. doi: 10.1167/iovs.08-1928. Epub 2008 Aug 29.

PMID:
18757510
44.

Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.

Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS.

Retina. 2008 Oct;28(8):1151-8. doi: 10.1097/IAE.0b013e31817e100f.

PMID:
18685542
45.

Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections.

de Caro JJ, Ta CN, Ho HK, Cabael L, Hu N, Sanislo SR, Blumenkranz MS, Moshfeghi DM, Jack R, de Kaspar HM.

Retina. 2008 Jun;28(6):877-83. doi: 10.1097/IAE.0b013e31816b3180.

PMID:
18536606
46.

Severe surfing-related ocular injuries: the Stanford Northern Californian experience.

Zoumalan CI, Blumenkranz MS, McCulley TJ, Moshfeghi DM.

Br J Sports Med. 2008 Oct;42(10):855-7. doi: 10.1136/bjsm.2007.041657. Epub 2008 Jan 15. Erratum in: Br J Sports Med. 2009 Apr;43(4):310-1.

PMID:
18198199
47.

Effect of pulse duration on size and character of the lesion in retinal photocoagulation.

Jain A, Blumenkranz MS, Paulus Y, Wiltberger MW, Andersen DE, Huie P, Palanker D.

Arch Ophthalmol. 2008 Jan;126(1):78-85. doi: 10.1001/archophthalmol.2007.29.

PMID:
18195222
48.

Endogenous Scedosporium apiospermum endophthalmitis.

Jain A, Egbert P, McCulley TJ, Blumenkranz MS, Moshfeghi DM.

Arch Ophthalmol. 2007 Sep;125(9):1286-9. No abstract available.

PMID:
17846376
49.

Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Ronan SM, Yoganathan P, Chien FY, Corcóstegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, López M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN.

Retina. 2007 Jun;27(5):535-40.

PMID:
17558313
50.

Role of genetic factors and inflammation in age-related macular degeneration.

Moshfeghi DM, Blumenkranz MS.

Retina. 2007 Mar;27(3):269-75. Review.

PMID:
17460581

Supplemental Content

Loading ...
Support Center